Grail: A Potential Sleeper Stock in Liquid Biopsies
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 08 2026
0mins
Source: Fool
- Massive Market Opportunity: With a market cap of approximately $2.6 billion, Grail focuses on early cancer detection through its Galleri test, which screens for over 50 cancer types, including ovarian, pancreatic, and liver/bile duct cancers that currently lack screening options, highlighting its significant potential in the projected $50 billion liquid biopsy market.
- Significant Clinical Results: At the 2026 American Society of Clinical Oncology Annual Meeting, Grail presented results from the NHS Galleri 2 and Pathfinder 2 trials, demonstrating that Galleri reduced stage IV diagnoses of 12 cancer types by over 20% and detected four times as many cancers when added to standard care, underscoring its effectiveness in early cancer detection.
- FDA Application Progress: Grail submitted its application for full FDA approval of Galleri in January 2026, and if approved, insurers are likely to quickly begin reimbursing the test, further enhancing market acceptance, especially with the support of the Medicare Multi-Cancer Early Detection Screening Coverage Act.
- Investment Risks and Rewards: Despite reporting a net loss of $93.2 million in Q1 2026 and facing competition from Exact Sciences and Guardant Health, Grail's stock could skyrocket if it secures FDA approval and payer reimbursements, making it a focal point for patient investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GRAL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GRAL
Wall Street analysts forecast GRAL stock price to rise
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 60.160
Low
38.00
Averages
60.86
High
83.71
Current: 60.160
Low
38.00
Averages
60.86
High
83.71
About GRAL
Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
GRAIL, Inc. Faces Class Action for Securities Fraud
- Lawsuit Background: Leading securities law firm Bleichmar Fonti & Auld LLP has announced a class action lawsuit against GRAIL, Inc. and certain executives for securities fraud related to the NHS-Galleri cancer trial, highlighting serious investor concerns regarding the company's transparency and compliance.
- Stock Price Plunge: On February 19, 2026, GRAIL disclosed preliminary results from the NHS-Galleri trial, which, despite some favorable data, failed to meet its primary endpoint, causing the stock price to plummet from $101.53 to $50.21, a staggering 50.55% drop that directly undermined investor confidence.
- Legal Proceedings: Investors have until August 4, 2026, to apply to lead the case, which is pending in the U.S. District Court for the Northern District of California, asserting claims under Sections 10(b) and 20(a) of the Securities Exchange Act, raising questions about corporate governance and compliance.
- Strategic Impact: GRAIL's focus on early cancer detection through its Galleri test may be jeopardized by the trial's failure, potentially hindering its implementation as a national screening program within the UK's National Health Service, thereby negatively affecting the company's long-term growth prospects and necessitating close monitoring of future developments.
See More
Reminder of Class Action Lawsuit Against GRAIL, Inc.
- Class Action Notice: The Schall Law Firm reminds investors of a class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5, with a deadline for contact set for August 4, 2026.
- Investor Losses: Investors who purchased GRAIL securities between May 13, 2025, and February 19, 2026, are encouraged to join the lawsuit due to misleading statements regarding the NHS-Galleri trial, which resulted in significant investor losses when the truth emerged.
- False Statement Allegations: The complaint alleges that GRAIL made false and misleading statements about the NHS-Galleri trial's prospects, overstating its potential success while concealing adverse data, leading to investor damages once the truth was revealed.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations for affected shareholders to discuss their rights, emphasizing that the class has not yet been certified, meaning investors are not currently represented by an attorney.
See More
Class Action Lawsuit Announced for GRAIL, Inc.
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of GRAIL, Inc. (NASDAQ: GRAL) common stock purchasers between May 13, 2025, and February 19, 2026, aiming to seek compensation for investors, reflecting potential misleading statements made by the company during this period.
- Compensation Structure: Investors participating in the lawsuit will not incur any upfront costs due to a contingency fee arrangement, which reduces the financial burden on investors and encourages more affected shareholders to join the litigation for justice.
- Case Details Revealed: The lawsuit alleges that GRAIL provided overly optimistic statements regarding its NHS-Galleri trial while concealing significant adverse facts related to the trial results, leading to investor losses once the true information was disclosed, highlighting a lack of corporate governance and transparency.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, indicating its expertise and influence in handling similar cases, thereby boosting investor confidence in this lawsuit.
See More
Grail Class Action Lawsuit Initiated
- Lawsuit Background: Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against Grail, Inc. (NASDAQ: GRAL), representing shareholders who purchased stock between May 13, 2025, and February 19, 2026, alleging violations of the Securities Exchange Act of 1934 by top executives.
- False Statements Allegations: The lawsuit claims that Grail misrepresented its ability to significantly reduce late-stage cancer rates in the NHS-Galleri trial while concealing adverse facts that undermined the likelihood of achieving this outcome, misleading investors about the company's prospects.
- Stock Price Plunge: On February 19, 2026, Grail announced that a statistically significant reduction in late-stage cancers was not observed, leading to a stock price drop of over 50%, resulting in substantial losses for investors.
- Investor Rights: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Grail stock during the class period can seek appointment as lead plaintiff, representing other shareholders in pursuit of damages, highlighting the importance of protecting investor rights.
See More
Multiple Companies Face Class Action Lawsuits
- Badger Meter Lawsuit: Badger Meter, Inc. faces a class action lawsuit for failing to disclose weakening customer orders and poor financial results during the period from April 18, 2024, to April 16, 2026, with a lead plaintiff deadline of July 27, 2026, potentially damaging the company's reputation and stock price.
- PicS N.V. Lawsuit: PicS N.V. is being sued for not disclosing deficiencies in its credit evaluation procedures and declining customer credit quality during the period from January 27, 2026, to June 5, 2026, with a lead plaintiff deadline of August 4, 2026, which may impact the company's future financing capabilities and market trust.
- Verra Mobility Lawsuit: Verra Mobility Corporation faces a class action lawsuit for not disclosing its reliance on a contract with Avis during the period from February 24, 2026, to May 26, 2026, with a lead plaintiff deadline of August 4, 2026, potentially leading to downward revisions in performance expectations and stock price volatility.
- Grail, Inc. Lawsuit: Grail, Inc. is being sued for management's overly optimistic confidence in clinical trial results during the period from May 13, 2025, to February 19, 2026, with a lead plaintiff deadline of August 4, 2026, which may affect the company's future financing and market confidence.
See More
Investigation Launched into Grail Securities Litigation
- Investigation Initiated: Faruqi & Faruqi, LLP is investigating potential claims against Grail, Inc., specifically targeting investors who purchased securities between May 13, 2025, and February 19, 2026, and reminding them to apply for lead plaintiff status by August 4, 2026, to represent other investors in the federal securities class action.
- Stock Price Plunge: Following Grail's announcement on February 19, 2026, that the NHS-Galleri trial did not observe a statistically significant reduction in Stage III-IV cancers, the stock price plummeted from $101.53 to $50.21 per share, marking a dramatic decline of approximately 50.55% in just one day, resulting in significant losses for investors.
- False Statements Revealed: Grail executives had repeatedly expressed confidence in the success of the NHS-Galleri trial, claiming its design was sufficient to demonstrate a statistically significant reduction, while concealing the fact that the trial period was inadequate to achieve the primary endpoint, misleading investors.
- Legal Rights Reminder: Faruqi & Faruqi encourages all investors who purchased Grail stock during the class period and suffered losses to contact them to discuss their legal rights, ensuring that investors can secure their rightful compensation in any future claims.
See More
GRAIL, Inc. Faces Class Action for Securities Fraud
- Lawsuit Background: Leading securities law firm Bleichmar Fonti & Auld LLP has announced a class action lawsuit against GRAIL, Inc. and certain executives for securities fraud related to the NHS-Galleri cancer trial, highlighting serious investor concerns regarding the company's transparency and compliance.
- Stock Price Plunge: On February 19, 2026, GRAIL disclosed preliminary results from the NHS-Galleri trial, which, despite some favorable data, failed to meet its primary endpoint, causing the stock price to plummet from $101.53 to $50.21, a staggering 50.55% drop that directly undermined investor confidence.
- Legal Proceedings: Investors have until August 4, 2026, to apply to lead the case, which is pending in the U.S. District Court for the Northern District of California, asserting claims under Sections 10(b) and 20(a) of the Securities Exchange Act, raising questions about corporate governance and compliance.
- Strategic Impact: GRAIL's focus on early cancer detection through its Galleri test may be jeopardized by the trial's failure, potentially hindering its implementation as a national screening program within the UK's National Health Service, thereby negatively affecting the company's long-term growth prospects and necessitating close monitoring of future developments.
See More
Reminder of Class Action Lawsuit Against GRAIL, Inc.
- Class Action Notice: The Schall Law Firm reminds investors of a class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5, with a deadline for contact set for August 4, 2026.
- Investor Losses: Investors who purchased GRAIL securities between May 13, 2025, and February 19, 2026, are encouraged to join the lawsuit due to misleading statements regarding the NHS-Galleri trial, which resulted in significant investor losses when the truth emerged.
- False Statement Allegations: The complaint alleges that GRAIL made false and misleading statements about the NHS-Galleri trial's prospects, overstating its potential success while concealing adverse data, leading to investor damages once the truth was revealed.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations for affected shareholders to discuss their rights, emphasizing that the class has not yet been certified, meaning investors are not currently represented by an attorney.
See More
Class Action Lawsuit Announced for GRAIL, Inc.
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of GRAIL, Inc. (NASDAQ: GRAL) common stock purchasers between May 13, 2025, and February 19, 2026, aiming to seek compensation for investors, reflecting potential misleading statements made by the company during this period.
- Compensation Structure: Investors participating in the lawsuit will not incur any upfront costs due to a contingency fee arrangement, which reduces the financial burden on investors and encourages more affected shareholders to join the litigation for justice.
- Case Details Revealed: The lawsuit alleges that GRAIL provided overly optimistic statements regarding its NHS-Galleri trial while concealing significant adverse facts related to the trial results, leading to investor losses once the true information was disclosed, highlighting a lack of corporate governance and transparency.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, indicating its expertise and influence in handling similar cases, thereby boosting investor confidence in this lawsuit.
See More
Grail Class Action Lawsuit Initiated
- Lawsuit Background: Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against Grail, Inc. (NASDAQ: GRAL), representing shareholders who purchased stock between May 13, 2025, and February 19, 2026, alleging violations of the Securities Exchange Act of 1934 by top executives.
- False Statements Allegations: The lawsuit claims that Grail misrepresented its ability to significantly reduce late-stage cancer rates in the NHS-Galleri trial while concealing adverse facts that undermined the likelihood of achieving this outcome, misleading investors about the company's prospects.
- Stock Price Plunge: On February 19, 2026, Grail announced that a statistically significant reduction in late-stage cancers was not observed, leading to a stock price drop of over 50%, resulting in substantial losses for investors.
- Investor Rights: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Grail stock during the class period can seek appointment as lead plaintiff, representing other shareholders in pursuit of damages, highlighting the importance of protecting investor rights.
See More
Multiple Companies Face Class Action Lawsuits
- Badger Meter Lawsuit: Badger Meter, Inc. faces a class action lawsuit for failing to disclose weakening customer orders and poor financial results during the period from April 18, 2024, to April 16, 2026, with a lead plaintiff deadline of July 27, 2026, potentially damaging the company's reputation and stock price.
- PicS N.V. Lawsuit: PicS N.V. is being sued for not disclosing deficiencies in its credit evaluation procedures and declining customer credit quality during the period from January 27, 2026, to June 5, 2026, with a lead plaintiff deadline of August 4, 2026, which may impact the company's future financing capabilities and market trust.
- Verra Mobility Lawsuit: Verra Mobility Corporation faces a class action lawsuit for not disclosing its reliance on a contract with Avis during the period from February 24, 2026, to May 26, 2026, with a lead plaintiff deadline of August 4, 2026, potentially leading to downward revisions in performance expectations and stock price volatility.
- Grail, Inc. Lawsuit: Grail, Inc. is being sued for management's overly optimistic confidence in clinical trial results during the period from May 13, 2025, to February 19, 2026, with a lead plaintiff deadline of August 4, 2026, which may affect the company's future financing and market confidence.
See More
Investigation Launched into Grail Securities Litigation
- Investigation Initiated: Faruqi & Faruqi, LLP is investigating potential claims against Grail, Inc., specifically targeting investors who purchased securities between May 13, 2025, and February 19, 2026, and reminding them to apply for lead plaintiff status by August 4, 2026, to represent other investors in the federal securities class action.
- Stock Price Plunge: Following Grail's announcement on February 19, 2026, that the NHS-Galleri trial did not observe a statistically significant reduction in Stage III-IV cancers, the stock price plummeted from $101.53 to $50.21 per share, marking a dramatic decline of approximately 50.55% in just one day, resulting in significant losses for investors.
- False Statements Revealed: Grail executives had repeatedly expressed confidence in the success of the NHS-Galleri trial, claiming its design was sufficient to demonstrate a statistically significant reduction, while concealing the fact that the trial period was inadequate to achieve the primary endpoint, misleading investors.
- Legal Rights Reminder: Faruqi & Faruqi encourages all investors who purchased Grail stock during the class period and suffered losses to contact them to discuss their legal rights, ensuring that investors can secure their rightful compensation in any future claims.
See More
